MedTrace Logo

Efficacy of Ivermectin in Adult Patients With Early Stages of COVID-19 (EPIC Trial)

NCT04405843 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 476

Last updated 2020-12-28

No results posted yet for this study

Summary

Double blind, placebo controlled, randomized clinical trial to evaluate the efficacy of ivermectin in preventing progression of disease in adult patients with early stages of COVID-19

Conditions

Interventions

DRUG

Ivermectin Oral Product

Ivermectin oral suspension, 6 mg/mL

DRUG

Placebo

Substance with similar physical and organoleptic characteristics as ivermectin, without the active drug ingredient

Sponsors & Collaborators

  • Centro de Estudios en Infectogía Pediatrica

    lead OTHER

Principal Investigators

  • Eduardo López-Medina, MD MSc · Scientific Director of Centro de Estudios en Infectología Pediátrica --CEIP--

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-14
Primary Completion
2020-12-21
Completion
2020-12-21

Countries

  • Colombia

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04405843 on ClinicalTrials.gov